Top 20 Global Chemical Companies by Revenue in 2025

Westlake Corporation announced its fourth-quarter and full-year 2025 financial results. Net sales for the quarter totaled $2.533 billion, down from $2.843 billion in the prior-year period. The company reported a net loss attributable to shareholders of $544 million for the quarter, compared to a net loss of $782 million in the same period last year. Full-year net sales amounted to $11.17 billion, down from $12.142 billion in 2024. Full-year net loss attributable to shareholders was $1.508 billion, versus net income of $602 million in 2024. International Flavors & Fragrances Inc. (IFF) announced its fourth-quarter and full-year 2025 financial results. Net sales for the quarter were $2.589 billion, down 7% year-on-year from $2.771 billion. Operating profit for the quarter stood at $97 million, down 24% from $127 million in the prior-year quarter. Net income attributable to shareholders was $18 million, compared to a net loss of $60 million in the same period last year. Full-year net sales totaled $10.89 billion, down 5% from $11.184 billion in 2024. Full-year operating loss was $382 million, versus operating income of $766 million in 2024. Full-year net loss attributable to shareholders was $374 million, compared to net income of $263 million in 2024. Celanese Corporation announced its fourth-quarter and full-year 2025 financial results. Net sales for the quarter were $2.204 billion, down from $2.358 billion in the prior-year period. Operating profit for the quarter was $93 million, versus an operating loss of $1.419 billion in the same period last year. Net income for the quarter was $22 million, versus a net loss of $1.922 billion in the prior-year quarter. Full-year net sales totaled $9.544 billion, down from $10.268 billion in 2024. Full-year operating loss was $786 million, versus an operating loss of $720 million in 2024. Full-year net loss was $1.151 billion, versus a net loss of $1.534 billion in 2024. Eastman Chemical Company announced its fourth-quarter and full-year 2025 financial results. Sales for the quarter were $1.973 billion, down from $2.245 billion in the prior-year period. Net income attributable to the company was $105 million, versus $330 million in the same period last year. Full-year sales totaled $8.752 billion, down from $9.382 billion in 2024. Net income attributable to the company was $474 million, versus $905 million in 2024. DuPont de Nemours, Inc. announced its fourth-quarter and full-year 2025 financial results. Net sales for the quarter were $1.693 billion, up slightly from $1.689 billion in the prior-year period. Net loss attributable to common shareholders was $126 million, versus a net loss of $117 million in the same period last year. Full-year net sales totaled $6.849 billion, up from $6.719 billion in 2024. Net loss attributable to common shareholders was $779 million, versus net income of $703 million in 2024. DuPont previously completed the spin-off of its Electronics Materials business into an independent, publicly traded company named Qnity Electronics. Huntsman Corporation announced its fourth-quarter and full-year 2025 financial results.

DuPont Acquires Again—Targeting the Healthcare Sector!

In recent years, DuPont has consistently intensified its strategic focus on the healthcare sector. In June 2022, DuPont officially opened its Liveo™ medical-grade silicone adhesive manufacturing facility in South Carolina, USA. In the same month, DuPont announced plans to expand its production capacity for silicone materials used in biopharmaceutical applications in China. In August 2023, DuPont completed the acquisition of Spectrum Plastics Group for $1.75 billion. Spectrum’s business partially overlapped with that of Donatelle Plastics, and it specialized in high-performance medical devices and components for structural heart disease, electrophysiology, surgical robotics, and cardiovascular applications. With nearly 60 years of history and over 400 employees, Donatelle Plastics possesses strong financial growth potential across key areas including electrophysiology, drug delivery, diagnostics, cardiac rhythm management, neuromodulation, and orthopedics. This strategic acquisition is intended to further strengthen DuPont’s market position in the medical device industry—signaling senior management’s strong confidence in the long-term growth trajectory of the healthcare equipment sector and underscoring its high strategic priority for upstream medical device markets. DuPont aims to deepen its presence and pursue both strategic transformation and expansion. By broadening its footprint in the medical device space, DuPont is poised to enhance its competitiveness in the healthcare market and challenge the leadership positions held by current industry incumbents. ▍Reclaiming Glory: A Century-Old Enterprise Reinvents Itself Over the past five years, DuPont has undergone two major corporate spin-offs and multiple rounds of business restructuring to proactively respond to global economic uncertainty and fragility. While divesting legacy businesses—including its Transportation & Materials segment—it has simultaneously reinforced its competitive advantages and expanded its portfolio in high-potential sectors such as medical materials, electronic materials, and water treatment. In Q1 2024, DuPont reported net sales of $2.9 billion and operating EBITDA of $682 million. Driven by optimism regarding the sustained recovery of the electronics market—and positive outlooks for industrial end-markets including water treatment and medical packaging—DuPont raised its full-year guidance for net sales, operating EBITDA, and adjusted earnings per share, forecasting sequential improvement in both sales and profitability. In May of this year, DuPont announced its formal tripartite spin-off into three independent, publicly traded companies: New DuPont (comprising the majority of the Industrial Solutions segment—including healthcare-related businesses—as well as the Water & Protection business and other retained operations), Electronics, and Water. See related article: “Doubling Down on Healthcare! Global Chemical Leader DuPont Splits Again.” New DuPont will serve global healthcare end-markets, offering products and services spanning biopharmaceutical consumables, medical devices, and medical packaging. New DuPont’s 2023 revenue totaled approximately $6.6 billion, with an operating EBITDA margin of 24%, primarily distributed across healthcare, mobility, and safety & protection—brands include Tyvek® and Kevlar®. In healthcare, DuPont’s flagship new offerings include the latest-generation Tyvek® medical packaging material—a high-density polyethylene fiber-based nonwoven technology—and Liveo® flexible skin-conductive tapes, silicone-based thermoset adhesives designed for electrophysiological signal sensing and transmission.

DuPont Swings to a Profit and Lifts Outlook

6 hours ago

DuPont de Nemours swung to a profit and raised its annual outlook following higher sales. It now anticipates adjusted earnings of $7.47 to $7.52 per share.

WSJ

2026-04-09

Oak Thistle LLC Acquires 46,908 Shares in DuPont de Nemours Inc.

2026-04-09

Oak Thistle LLC Acquires 46,908 Shares in DuPont de Nemours

2026-04-13

BMO Capital Markets Raises DuPont de Nemours Price Target to $60

2026-04-15

DuPont de Nemours Maintains Quarterly Dividend at $0.20 Per Share

2026-04-16

Robeco Institutional Asset Management B.V. Decreases Stake in DuPont de Nemours, Inc.